New York State Common Retirement Fund Sells 3,724,457 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York State Common Retirement Fund lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 98.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 76,228 shares of the biopharmaceutical company's stock after selling 3,724,457 shares during the period. New York State Common Retirement Fund owned 0.06% of Alnylam Pharmaceuticals worth $20,965,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company's stock worth $1,792,542,000 after purchasing an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock valued at $550,837,000 after buying an additional 201,784 shares during the last quarter. Capital International Investors raised its stake in Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company's stock worth $545,674,000 after acquiring an additional 64,560 shares during the period. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company's stock worth $470,018,000 after acquiring an additional 214,908 shares during the period. Finally, Bellevue Group AG lifted its holdings in Alnylam Pharmaceuticals by 3.7% in the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company's stock worth $137,238,000 after acquiring an additional 32,966 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 1.7 %

Shares of ALNY traded down $4.66 during mid-day trading on Tuesday, hitting $265.29. 966,724 shares of the company's stock were exchanged, compared to its average volume of 871,267. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a fifty day moving average of $274.63 and a two-hundred day moving average of $227.87. The stock has a market cap of $34.22 billion, a price-to-earnings ratio of -101.73 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period last year, the firm earned $1.15 EPS. The company's revenue was down 33.3% compared to the same quarter last year. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ALNY shares. Chardan Capital reiterated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. Royal Bank of Canada restated an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Finally, Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an "equal weight" rating in a research report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $294.50.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.